SRPT
Sarepta Therapeutics Inc
19.00$
-8.9%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| -500.0% | -500.0% | -100.0% | – | -32.1% | 2,202.5% | 2,969.1% | 1,892.9% | 5,479.2% | 424.4% | 26,896.3% | 383.1% | 169.1% | 180.3% | 93.3% | 76.5% | 139.1% | 635.0% | 964.5% | 11,667.5% | 2.4% | 4.8% | 11.4% | 14.9% | 11.7% | 13.8% | 15.0% | 12.1% | 16.8% | 40.1% | |
| 600.0% | 600.0% | 200.0% | 100.0% | 132.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 6.7% | 23.5% | -39.1% | -535.0% | -864.5% | 100.0% | 97.6% | 95.2% | 88.6% | 85.1% | 88.3% | 86.2% | 85.0% | 87.9% | 83.2% | 59.9% | |
| 1,700.0% | 2,700.0% | 3,150.0% | 6,700.0% | 714.4% | 1,805.8% | 2,678.6% | 1,575.9% | 4,817.8% | 357.8% | 21,984.0% | 316.4% | 136.4% | 138.7% | 122.3% | 142.3% | 140.4% | 512.8% | 965.8% | 11,683.5% | 3,473.0% | 107.8% | 133.5% | 147.3% | 133.7% | 109.9% | 94.0% | 70.6% | 42.3% | 69.2% | |
| 600.0% | 1,300.0% | 800.0% | 1,700.0% | 175.0% | 475.5% | 449.8% | 470.1% | 1,100.2% | 108.3% | 6,724.5% | 85.0% | 46.1% | 49.5% | 48.9% | 34.2% | 39.2% | 222.2% | 505.4% | 5,989.1% | 1,497.9% | 77.5% | 69.8% | 74.8% | 58.9% | 40.3% | 48.4% | 38.8% | 29.3% | 21.8% | |
| 2,800.0% | 4,500.0% | 4,050.0% | 8,400.0% | 921.5% | 2,281.4% | 3,128.4% | 2,046.0% | 5,917.9% | 466.2% | 28,708.5% | 401.4% | 182.5% | 188.2% | 171.2% | 176.5% | 179.6% | 735.0% | 1,471.2% | 17,672.5% | 5,017.9% | 187.9% | 202.8% | 270.4% | 192.7% | 151.7% | 142.5% | 109.4% | 71.8% | 89.8% | |
| -2,200.0% | -3,900.0% | -3,850.0% | -8,300.0% | -789.4% | -2,181.4% | -3,028.4% | -1,946.0% | -5,817.9% | -366.2% | -28,608.5% | -301.4% | -129.2% | -88.2% | -71.2% | -76.5% | -79.6% | -635.0% | -1,371.2% | -17,572.5% | -4,920.3% | -111.0% | -114.1% | -185.3% | -104.5% | -65.5% | -57.5% | -21.5% | 11.5% | -29.9% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.6% | 2.6% | 1.2% | 0.2% | 0.0% | 2.3% | 0.0% | 108.9% | 9.9% | 3.7% | 11.2% | 8.1% | 11.1% | 9.1% | 5.7% | 1.8% | 1.0% | 0.4% | |
| -2,000.0% | -3,500.0% | -13,350.0% | -8,400.0% | -712.2% | -1,172.4% | -3,508.6% | -1,507.1% | -5,756.1% | -348.6% | -26,951.8% | -256.3% | -112.7% | -140.5% | -81.4% | -4.9% | -324.9% | -787.6% | -1,391.7% | -17,560.3% | -4,930.2% | -31.5% | -120.5% | -187.5% | -102.4% | -59.7% | -73.9% | -41.8% | 13.7% | -31.9% | |
| 100.0% | -300.0% | 9,500.0% | – | – | 1,631.9% | 480.2% | -438.9% | – | – | – | -54.1% | 30.2% | 54.9% | 38.2% | -74.3% | 245.3% | 143.6% | -17.3% | -418.8% | -140.6% | 1.3% | -0.2% | 0.3% | 0.2% | 0.0% | 1.4% | 1.3% | 1.3% | 0.5% | |
| -2,100.0% | -3,600.0% | -13,350.0% | -8,300.0% | -712.2% | -3,813.2% | -3,508.6% | -1,507.1% | -5,756.1% | -348.6% | -26,951.8% | -247.3% | -112.7% | -143.1% | -109.4% | -4.9% | -324.9% | -787.6% | -1,391.7% | -17,560.3% | -4,930.2% | -32.8% | -120.2% | -187.8% | -102.6% | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% | |
| -1,700.0% | -3,400.0% | -3,800.0% | -8,000.0% | -757.3% | -2,102.5% | -2,869.0% | -1,792.9% | -5,317.5% | -306.8% | -26,795.4% | -229.0% | -105.8% | -80.3% | -66.2% | -73.7% | -73.9% | -621.8% | -1,332.1% | -17,153.8% | -4,816.8% | -22.5% | -105.2% | -173.0% | -83.9% | -45.2% | -63.8% | -36.5% | 16.7% | -29.5% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.